WHO ICTRP trial
Influence of B cell depletion therapy (rituximab) on (risk factors of)…
NL-OMON31299 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON31299 |
|---|---|
| Public title | Influence of B cell depletion therapy (rituximab) on (risk factors of) comorbidity in rheumatoid arthritis |
| Scientific title | Influence of B cell depletion therapy (rituximab) on (risk factors of) comorbidity in rheumatoid arthritis - B cell depletion therapy in rheumatoid arthritis and comorbidity |
| Primary sponsor | Vrije Universiteit Medisch Centrum |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Observational invasive |
| Countries | The Netherlands |
| Conditions | rheumatoid arthritis;10082206;10003816;10023213;rheumatoid arthritis |
| Interventions | ;comorbidity;rheumatoid arthritis;rituximab |
| Registration date | Mar 19, 2008 |
| Target size | 50 |
| Secondary IDs | NL18857.029.07 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: